Movatterモバイル変換


[0]ホーム

URL:


AU646501B2 - Filter for liquor filtration - Google Patents

Filter for liquor filtration
Download PDF

Info

Publication number
AU646501B2
AU646501B2AU86591/91AAU8659191AAU646501B2AU 646501 B2AU646501 B2AU 646501B2AU 86591/91 AAU86591/91 AAU 86591/91AAU 8659191 AAU8659191 AAU 8659191AAU 646501 B2AU646501 B2AU 646501B2
Authority
AU
Australia
Prior art keywords
filter
membrane
layer
filter layer
charge
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU86591/91A
Other versions
AU8659191A (en
Inventor
Michael W. K Saefkow
Kurt H Wollinsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pall Corp
Original Assignee
Pall Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pall CorpfiledCriticalPall Corp
Publication of AU8659191ApublicationCriticalpatent/AU8659191A/en
Application grantedgrantedCritical
Publication of AU646501B2publicationCriticalpatent/AU646501B2/en
Anticipated expirationlegal-statusCritical
Ceasedlegal-statusCriticalCurrent

Links

Classifications

Landscapes

Description

OPI DATE 28/04/92 AOJP DATE 11/06/92
INTERNAT
APPLN. ID P6591 91 PCT NUMBER PCT/EP91/01864 'REATY (PCT) (51) International Patent Classification 5 (11) International Publication Number: WO 92/05864 B1OD 69/02, A61M 1/36 (43) International Publication Date: 16 April 1992 (16.04.92) (21) International Application Number: PCT/EP91/01864 (74) Agents: DOST, Wolfgang et al.; Postfach 86 06 20, D-8000 M inchen 86 (DE).
(22) International Filing Date: 30 September 1991 (30.09.91) (81) Designated States: AU, CA, FI, JP, KR, NO, PL, SU+,US.
Priority data: 90119187.4 5 October 1990 (05.10.90) EP (34) Countriesfor which the regional Published or international application With international search report.
wasfiled: DE et al.
(71) Applicant (for all designated States except US): PALL COR- -L t- I PORATION [US/US]; 30 Sea Cliff Avenue, Glen Cove, 6 NY 11542 (US).
(72) Inventors; and Inventors/Applicants (for US only): WOLLINSKY, Kurt, H.
[DE/DE]; Shelmenweg 11, D-7901 Illerkirchoerg (DE).
SAEFKOW, Michael, K. [DE/DE]; Finkenweg 6, D- 6070 Langen (DE).
(54) Title: FILTER FOR LIQUOR FILTRATION (57) Abstract A filter for use in a process for the filtration of liquor cerbrospinalis comprises a membrane filter layer having a pore size of from 0.04 to 0.45 l.m and a thickness of from 0.1 to 1 mm, wherein said filter has a geometric surface area of _rom 15 to 300 cm 2 and a pyrogen separation capacity of at least 500 [g.
C -Cr WO 92/05864 PCT/EP9I/01864 -1- Filter for Liquor Filtration The invention relates to a filter for the filtration of liquor cerebrospinalis, in particular for the treatment of neurologic diseases which are accompanied by inflammable processes (neuritides, for example polyradiculitis, is radiculoneuritis or Guillain Barr6 syndrome (GBS), or which represent non-inflammable processes (neuropathies) as well as intoxications of the liquor (such as diphtheria or rabies) or infections by bacteria (for example borreliose) or viruses (for example virus encephalitis, polio), which manifest causally or symptomatically in the nervous system.
GBS, for example, is an ascending motoric and nerve-related paralysis and ascending nerve paralysis, respectively, including the lower brain nerves (which first extend to the extremities so that the patient cannot walk any more and becomes bed ridden, respectively, and can lead to a total paralysis of all muscles so that a long-term aspirator treatment of the patient is required. A degeneration of nerves with long-time defects is possible.
The aforesaid diseases cause a change of the liquor composition. The reasons for these symptoms are still unclear, and in particular a causality between the changed liquor composition and the disease symptoms has not been established. The therapy of the Guillain Barr6 syndrome consists in the therapeutic plasmapheresis, i. a (partial) plasma exchange, SUBSTITUTE
SHEET
WO 92/05864 PCT/EP91/01864 -2wherein, after blood withdrawal from the patient, a mechanical separation of corpuscular elements and plasma, for example by centrifuging, occurs.
The corpuscular constituents, after total or partial volume replacement of the withdrawn plasma, are resuspended in the plasma substitute and s reinfused into the patient. With numerous patients, however, the method of plasmapheresis produces little or no improvement in the disease symptoms.
It has now been found that the latter causes a substantial improvement in the condition of the patient, and complete alleviation of symptoms can be achieved if the liquor of this patent is subjected o a filtration through a specific filter.
Accordingly, the invention relates to a filter for use in a method for the is filtration of liquor cerebrospinalis, which filter is characterized by a membrane filter layer having a pore width of from 0.04 to 0.45 gim and a thickness of from 0.1 to 1 mm, wherein said filter has a geometric surface area of from 50 to 300 cm 2 and a pyrogen separation capacity of at least 500 ig.
The pyrogen separation capacity, given in ig, means that the filter withholds the stated amount of pyrogen, based on a standard E. coli endotoxin in a concentration range of between 0.6 and 6.9 ng/ml in the starting material, wherein the concentration in the filtrate is below the limit of the LAL test (limulus-amoebocytes-lysate test) (about 0.006 ng/ml).
Pyrogenic compounds (pyrogens) (fever-generating compounds) are primarily heat-resistant, dialyzable compounds of a pathogenic and pathogenic bacteria, fungi or viruses which, when administered to man in SUBSTITUTE SHEET WO 92/05864 PCT/EP91/01864 -3extremely small amounts 1 jg/kg) cause shivers and an increase in temperature (fever). In terms of their chemical character, pyrogenic compounds are mainly oligo, poly- and lipopolysaccharides or polypeptides, wherein the strongest effective pyrogenic compounds are those of Gram s negative bacteria.
Pyrogenic compounds are of importance as impurities in injection or infusion solutions from which they must be removed by means of socalled bacteria filters. By definition these bacteria filters are microporous materials by means of which bacteria can be removed from gases or liquids by sieve or adsorption effect, for example glass, membrane or sieve filters (cf. Roche Lexikon Medizin, 1st Edition 1984, page 135). The determination of the pyrogen separation capacity occurs by use of a standard pyrogenic compound, i. with an E. coli endotoxin, wherein the efficiency of the separation is checked with the rabbit test or the LAL test (cf. Pharm. Ind. 47 (1985) 407 411). Commercial bacteria filters which are used as infusion filters for the protection of patients have pyrogen separation capacities below 100 gg, and a geometric filter area of about 10 cm 2 The use of the filter according to the invention is a method whereby the filtering of liquor cerebrospinalis can be carried out in a very simple manner. In practice it has been found that 5uch a simple and convenient method is one whereby after inserting in the patient an intrathecal 2s catheter comprising two three-way cocks, a 10 ml syringe and the liquor filter, a closed systcrn is installed. Then, 10 40 ml liquor each are manually withdrawn and replaced after passage through the filter. With this method 6 GBS patients were treated, 4 having an acute and 2 having a chronic history. With 3 of the patients intensive plasmapheresis carried out before had been without effect on their symptoms. In 1 to SUBSTITUTE SHEET WO 92/05864 PCTEP91/01864 -4- 2 daily treatments for up to 5 days a maximum of 150 ml liquor each was filtrated. The method was tolerated well by all patients and without complications. Headaches occurred only fleetingly and were not as intense as is usually observed with lumbar punctures. With all patients there s could be observed, timely related to the liquor filtration, and sometimes during the treatmr.ent, pronounced, or sometimes a significant improvement in the clinical symptoms. With acute patients and patients treated in early stages of GBS the improvement was more pronounced and faster than in the case of chronic patients.
A filtration of the liquor can also be indicated with other symptoms which are accompanied by a change of the liquor, for example with multiple Sclerosis or ALS.
The membrane filter layer of the filter of the invention has a pore size of from 0.04 to 0.45 pm, preferably from 0.1 to 0.3 pim and most preferably from 0.1 to 0.2 Membrane filter layers having such a pore size are known per se and are used in bacteria filters for the administration of infusion solutions, wherein membranes having a pore size below 0.1 jpm are also used as virus filters. The common bacteria filters are, however, not suitable in accordance with the invention since when using same for liquor filtration, no significant change is achieved. In addition, because of the uncertain causes of the Guillain Barr6 syndrome, a significant improvement of the symptoms of the disease could not be expected with the claimed filter.
The filter of the invention has a pyrogen separation capacity of at least 500 jig, for example at least 600 or 700 pg, and preferably of at least 1000 pg, wherein a range of from 1000 to 2000 pg is especially preferred.
SUBSTITUTE
SHEET
WO 92/05864 PCT/EP91/01864 The membrane filter layer has a layer thickness of from 0.1 to 1 mm, wherein said filter has a geometric surface area of from 50 to 300 cm 2 Within the said ranges of from 0.04 to 0.45 pim for the pore width, to 300 cm 2 for the geometric surface area and 0.1 to 1 mm for the thickness of the membrane filter layer, a correlation is made so that the required pyrogen separation capacity of at least 500 plg and a flow rate sufficient for practical use is achieved.
In general the flow rate is about proportional to the pore width and the surface area and about inversely proportional to the layer thickness, whereas the separation capacity is proportional to the layer thickness and to the geometric surface area.
A further parameter for controlling the pyrogen separation capacity and the flow rate is the pore volume, expressed as percentage of the pore volume based on the total volume, wherein within certain limits both the separation capacity and the flux rate are about proportional to the pore volume. The pore volume should be as high as possible in order to be able to keep the filter as small as possible. The pore volume, however, has upper limits. In practice the pore volume is generally 50 90 wherein for the afore-stated reason the higher values are preferred. As material for the membrane filter layer all inert polymeric materials are convenient from which membranes with the 5tated pore ranges can be made according to known methods. Examples for suitable materials are plastics inert against body fluids, such as polyolefines, for example polyethylene or polypropylene, polyamides, for example nylon 6,6 or polycaprolactame, polyester or polyvinylidene fluoride.
In a preferred embodiment the membrane filter layer is a chargemodified membrane for the reason that the separation capacity can be SUBSTITUTE SHEET WO 92/05864 PCT/EP91/01864 -6achieved moved easily in this way. Charge-modified membranes both with positive zeta potential and with negative zeta potential are commercially available. The preferred charge-modified membranes are those which have been made by adding a charge modifying agent to the dope solution from which the membrane is cast.
The charge-modified membranes having a positive zeta potential are also designated as cationic membranes. A suitable membrane is, for example, of a polyamide, for example nylon 6,6, wherein the charge modification 0o of the membrane is accomplished by adding a heat-settable polymer carrying quaternary ammonium groups, to the polymer dope. Since the positive charge of these membranes stems from the presence of the quaternary ammonium groups, they maintain their positive charge in acidic, neutral and alkaline pH range.
The charge-modified membranes having a negative zeta potential are also designated as anionic membranes. Sources for the negative charge are ionizable functional polar groups, such as carboxylic acid groups, sulfonic acid groups, phenolic amino groups, sulfhydryl-, sulfide-, thiocarbonyl-, phosphine-, phosphoryl-or thiophosphoryl groups. Carboxyl groups are preferred.
In a further preferred embodiment the filter of the invention is a composite filter, wherein the filter comprises a second membrane filter layer having a pore size in the range of 0.1 to 5 pm and a thickness of 0.1 to 1 mm. In this case the first membrane filter layer can be made very thin, since its function remains only in separating bacteria and viruses, respectively, whereas in the second (preceding) layer the major amount of deliterious constituents has already occurred though adsorption.
In this embodiment the essential part of the separation capacity is thus SUBSTITUTE SHEET WO 92/05864 PCT/EP91/01864 -7provided by the preceding second layer. The primary importance of the second filter layer is in the adsorption capacity rather than in the pore size, and for this reason a larger pore size, for example of 0.8 j/m or 1.2 gm or up to 5 jpm is suitable as well. The smaller pore size yields, however, better results with the second layer as well, and for this reason a pore size of from 0.1 to 0.45 /m is preferred.
The thickness of the second filter layer is from 0.1 to 1 mm. With increasing pore size (and with increasing pore volume), caused by the i0 higher flow rate, the layer thickness can be increased which, on the other hand, allows a change in the geometric surface area of the filter in the range of from 50 to 300 cm 2 to smaller values while maintaining the minimum pyrogen separation capacity of 500 pig.
1a Thus the filter of the invention is one-layered or multi-layered. With the one-layered embodiment the single membrane filter layer is preferably a charge-modified membrane such as described hereinbefore.
With the multi-layered embodiment the composite filter consists of at least two layers, wherein preferably the second (preceding) filter layer is a charge-modified membrane. In a specific embodiment of this composite filter the first filter layer is a charge-neutral membrane, for example from nylon 6,6, and the second filter layer is a charge-modified membrane, wherein the charge can be either positive or negative (positive or negative zeta potential). In a further specific embodiment of a twolayered filter the first layer is a positively charge-modified membrane and the second (preceding) layer is a negatively charge-modified membrane.
In a further specific embodiment of a three-layered filter the second layer is a positively charge-modified membrane and the third layer is a negatively charge-modified membrane.
SUBSTITUTE
SHEET
WVO 92/05864 PCT/EP9/01864 -8- For practical use the filter of the invention, irrespective of the number and kind of its layers, has one or more supporting or carrier layers which impart mechanical strength to the filter, without changing its use properties. Furthermore, for practical use the filter is preferably arranged s in a filter housing with corresponding connections, wherein the aforesaid supporting layers can also be integrated into said filter housing.
In a further preferred embodiment the filter of the invention is equipped with a means of venting. It has been found that gas bubbles can develop during the operation of the liquor filter, which gas bubbles can lead to a blocking of the filter. The venting enables these gas bubbles to escape from the filter housing while maintaining sterility. A suitable venting is, for example, a usual venting valve. Preferably this purpose is achieved by a venting membrane which is a hydrophobic membrane having a pore size such that leaking of liquor liquid is prevented but gas bubbles can pass through at the filtration pressure. The venting membrane is arranged at the intake side of the filter housing, i. on that side at which the liquor to be filtered enters the filter housing.
The following drawings illustrate the invention, wherein Figures 1 4 show, in schematic presentation, one-layered and multi-layered embodiments of liquor filters of the invention as follows: Figure 1 a one-layered membrane filter layer for a liquor filter of the invention, Figure 2 a two-layered embodiment, Figure 3 also a two-layered embodiment, and SUBSTITUTE SHEET WO 92/05864 PCT/EP91/01864 -9- Figure 4 a three-layered embodiment.
Only the respective layers are shown without supporting layers and housing.
Figure 1 shows a membrane filter layer 11 having a layer thickness of 0.2 mm and a pore size of 0.2 pm. The material is nylon-6,6, wherein the membrane has been charge-modified by the introduction of quaternary ammonium groups so that a positive zeta potential is prevailing. Similar membranes are commercially available from, for example, Pall Corporation under its trademark Posidyne®.
The above membrane filter layer is used to make a liquor filter which, at a geometric surface area of the filter of 160 cm 2 has a pyrogen is separation capacity of 560 pg.
Figure 2 shows a two-layered embodiment. The first layer 21 is of nylon- 6,6 and has a thickness of 0.1 mm and a pore size of 0.04 gm. This first layer 21 is preceded by a second layer 22 of the Posidyne® material from Figure 1, layer thickness 0.2 mm, pore size 0.2 pm.
At a geometric surface area of 160 cm 2 a filter made therefrom has a pyrogen separation capacity of 560 pg. Because of the pore size of 0.04 gm for the first layer 21 the composite filter is virus-retentive.
In Figure 3 the first membrane filter layer 31 is of Posidyne® having a thickness of 0.2 mm and a pore size of 0.2 p/m. The second layer 32 is a negatively charge-modified membrane, i. e. a membrane having a negative zeta potential. Such membranes are commercially available from, SUBSTITUTE SHEET WO 92/05864 PCT/EP91/01864 10 for example, Pall Corporation under its trademark Carboxydyne®. The second layer 32 has a thickness .of 0.2 mm and a pore size of 0.2 im.
A liquor filter made from the aforesaid composite material shows a s pyrogen separation capacity of 560 /g at a geometric surface area of 160 cm 2 In Figure 4 the first layer 41 has a thickness of 0.1 mm, a pore size of 0 J4 gm and is of nylon-6,6. This first layer 41 takes care of the virus retention similar to the composite filter of Figure 2.
The second layer 42 is a Posidyne® membrane having a thickness of 0.2 mm add a pore size of 0.2 jim.
The third layer 43 has a thickness of 0.2 and is a Carboxydyne® membrane.
A liquor filter made from the aforesaid pyrogen separation capacity of 560 jg at a cm2 mm, a pore size of 0.04 jam composite material shows a geometric surface area of 160 SUBSTITUTE SHEET

Claims (14)

1. A Filter for use in a process for the filtration of liquor cerebrospinalis, characterized by a membrane filter layer having a pore size of 0.04 to 0.45 pjm and a layer thickness of from 0.1 to 1 mm, wherein said filter has a geometric surface area of from 15 to 300 cm 2 and a pyrogen separation capacity of at least 500 jg.
2. The filter of claim 1 characterized in that the membrane filter layer has a pore size of from 0.1 to 0.3 /m. is
3. The filter of claim 2 characterized in that the membrane filter layer has a pore size of from 0.1 to 0.2 m.
4. The filter of any of claims 1 3 characterized in that the membrr e filter layer has a pyrogen separation capacity of from 1000 to 2000 pg.
The filter of any of claims 1 4 characterized in that the memb;,ie filter layer is of a polyamide.
6. The filter of any of claims 1 4 characterized in that the membrane filter layer is a charge-modified membrane.
7. The filter of claim 1 characterized in that it is constructed as composite filter, wherein the membrane filter layer is preceded by SUBSTITUTE SHEET WO 92/05864 PCT/EP91/01864 12 a second membrane filter layer having a re size in the range of 0.1 to 5 pm and a thickness of 0.1 to 1 mm.
8. The filter of claim 7 characterized in that the second membrane filter layer has a pore size of from 0.1 to 0.45 gm.
9. The filter of claim 7 or 8 characterized in that the second mem- brane filter layer (22, 32, 42) is a charge-modified membrane having a positive zeta potential.
The filter of claim 7 or 8 characterized in that the first membrane filter layer (31) is a charge-modified membrane having a positive zeta potential, and the second membrane filter layer (32) is a charge-modified membrane having a negative zeta potential.
11. The filter of claim 7 or 8 characterized in that the second mem- brane filter layer (42) is a charge-modified membrane having a positive zeta potential, and a third membrane filter layer (43) is a charge-modified membrane having a negative zeta potential.
12. The filter of claim 9 or 11 characterized in that the first membrane filter layer (21, 41) serving virus retention has a pore size below 0.1 ijm, preferably 0.04 um.
13. The filter of any of claims 1 12 characterized by the presence of one or more supporting layers providing mechanical strength to the filter without changing the filtering properties.
14. The filter of any of claims I 13 characterized by the presence of a filter housing with connection pieces for retaining the filter. SUBSTITUTE SHEET WO 92/05864 PCT/EP91/01864 13- The filter of claim 14 characterized by the presence of a venting membrane at the intake side of the filter housing. SUBSTITUTE SHEET
AU86591/91A1990-10-051991-09-30Filter for liquor filtrationCeasedAU646501B2 (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
EP19900119187EP0478842A1 (en)1990-10-051990-10-05Filter for the filtration of human cerebrospinal fluid
EP901191871990-10-05

Publications (2)

Publication NumberPublication Date
AU8659191A AU8659191A (en)1992-04-28
AU646501B2true AU646501B2 (en)1994-02-24

Family

ID=8204586

Family Applications (1)

Application NumberTitlePriority DateFiling Date
AU86591/91ACeasedAU646501B2 (en)1990-10-051991-09-30Filter for liquor filtration

Country Status (13)

CountryLink
US (1)US5462667A (en)
EP (2)EP0478842A1 (en)
JP (1)JP3233928B2 (en)
KR (1)KR100187556B1 (en)
AU (1)AU646501B2 (en)
CA (1)CA2092553C (en)
DE (1)DE69128679T2 (en)
FI (1)FI104237B (en)
IE (1)IE80682B1 (en)
NO (1)NO303768B1 (en)
PT (1)PT99148B (en)
RU (1)RU2072889C1 (en)
WO (1)WO1992005864A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5334315A (en)*1992-01-171994-08-02Pall CorporationPriming system
GB9218239D0 (en)*1992-08-271992-10-14Pall CorpProcessing of protein-containing body fluids
CA2183154A1 (en)*1994-02-141995-08-17Nicholas John DeaconNon-pathogenic strains of hiv-1
AU3653097A (en)*1996-07-081998-02-02Memtec America CorporationCationically charge-modified membranes
US5980480A (en)*1996-07-111999-11-09Cs Fluids, Inc.Method and apparatus for treating adult-onset dementia of the alzheimer's type
US6689085B1 (en)1996-07-112004-02-10Eunoe, Inc.Method and apparatus for treating adult-onset dementia of the Alzheimer's type
US7189221B2 (en)1998-11-102007-03-13Integra Life Sciences CorporationMethods for the treatment of a normal pressure hydrocephalus
US6875192B1 (en)1998-11-102005-04-05Eunoe, Inc.Devices and methods for removing cerebrospinal fluids from a patient's CSF space
DE60027811T2 (en)*1999-03-112006-10-19Medtronic, Inc., Minneapolis Hydrophobic vent built into a drainage chamber for cerebrospinal fluid
US6629919B2 (en)*1999-06-032003-10-07Haemonetics CorporationCore for blood processing apparatus
EP1057534A1 (en)*1999-06-032000-12-06Haemonetics CorporationCentrifugation bowl with filter core
EP1110596B1 (en)1999-12-232004-07-07Membrana GmbHShaped body for the retention of pyrogenes, process for its manufacture and use thereof
US6596112B1 (en)2000-10-202003-07-22Pall CorporationLaminates of asymmetric membranes
CN101346167B (en)*2005-12-282011-04-13株式会社岛津制作所Pressure difference air bubble moving control method and gas exchange apparatus adopting the same, electric conductivity measuring apparatus, total organic carbon measuring equipment, reaction device and cell culture device
US8435204B2 (en)2006-10-092013-05-07Neurofluidics, Inc.Cerebrospinal fluid purification system
US10850235B2 (en)2006-10-092020-12-01Minnetronix, Inc.Method for filtering cerebrospinal fluid (CSF) including monitoring CSF flow
US10632237B2 (en)2006-10-092020-04-28Minnetronix, Inc.Tangential flow filter system for the filtration of materials from biologic fluids
US8383865B2 (en)*2007-04-172013-02-26Codman & Shurtleff, Inc.Curcumin derivatives
EP2136797A4 (en)*2007-04-172013-08-21Codman & ShurtleffIntranasally administering curcumin in a bolus of helium gas to treat alzheimer's disease
US7745670B2 (en)*2008-06-272010-06-29Codman & Shurtleff, Inc.Curcumin-Resveratrol hybrid molecule
US8454548B2 (en)2008-04-142013-06-04Haemonetics CorporationSystem and method for plasma reduced platelet collection
US8702637B2 (en)2008-04-142014-04-22Haemonetics CorporationSystem and method for optimized apheresis draw and return
US8628489B2 (en)2008-04-142014-01-14Haemonetics CorporationThree-line apheresis system and method
US8177978B2 (en)*2008-04-152012-05-15Nanoh20, Inc.Reverse osmosis membranes
US7985776B2 (en)2008-06-272011-07-26Codman & Shurtleff, Inc.Iontophoretic delivery of curcumin and curcumin analogs for the treatment of Alzheimer's Disease
US7723515B1 (en)*2009-01-262010-05-25Codman & Shurtleff, Inc.Methylene blue—curcumin analog for the treatment of alzheimer's disease
US20100286585A1 (en)*2009-01-262010-11-11Codman & Shurtleff, Inc.Shunt Delivery of Curcumin
US8834402B2 (en)2009-03-122014-09-16Haemonetics CorporationSystem and method for the re-anticoagulation of platelet rich plasma
WO2011008549A2 (en)2009-06-292011-01-20NanoH2O Inc.Improved hybrid tfc ro membranes with nitrogen additives
CN103221078B (en)2010-11-052015-09-16赫摩耐提克斯公司 Systems and methods for automated platelet washing
US8801935B2 (en)2010-11-102014-08-12Nanoh2O, Inc.Hybrid TFC RO membranes with non-metallic additives
US9302042B2 (en)2010-12-302016-04-05Haemonetics CorporationSystem and method for collecting platelets and anticipating plasma return
US11386993B2 (en)2011-05-182022-07-12Fenwal, Inc.Plasma collection with remote programming
US11147540B2 (en)2015-07-012021-10-19Minnetronix, Inc.Introducer sheath and puncture tool for the introduction and placement of a catheter in tissue
EP3331586B1 (en)2015-08-052020-04-29Minnetronix Inc.Tangential flow filter system for the filtration of materials from biologic fluids
US9861940B2 (en)2015-08-312018-01-09Lg Baboh2O, Inc.Additives for salt rejection enhancement of a membrane
JP6654242B2 (en)2015-12-042020-02-26ミネトロニクス, インコーポレイテッド System for treating cerebrospinal fluid
US9737859B2 (en)2016-01-112017-08-22Lg Nanoh2O, Inc.Process for improved water flux through a TFC membrane
US10155203B2 (en)2016-03-032018-12-18Lg Nanoh2O, Inc.Methods of enhancing water flux of a TFC membrane using oxidizing and reducing agents
US10792416B2 (en)2017-05-302020-10-06Haemonetics CorporationSystem and method for collecting plasma
US10758652B2 (en)2017-05-302020-09-01Haemonetics CorporationSystem and method for collecting plasma
US11065376B2 (en)2018-03-262021-07-20Haemonetics CorporationPlasmapheresis centrifuge bowl
EP4186540A1 (en)2018-05-212023-05-31Fenwal, Inc.Systems and methods for optimization of plasma collection volumes
US11412967B2 (en)2018-05-212022-08-16Fenwal, Inc.Systems and methods for plasma collection
US12033750B2 (en)2018-05-212024-07-09Fenwal, Inc.Plasma collection
CN114107954A (en)*2021-11-152022-03-01合肥欣奕华智能机器有限公司 Atomic layer deposition equipment

Citations (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3591493A (en)*1968-06-171971-07-06Rashid A ZeinehMethod for the treatment of biological fluids and apparatus therefor
EP0080680A2 (en)*1981-11-271983-06-08Sentron v.o.f.Reference electrode catheter
EP0098392A2 (en)*1982-07-021984-01-18Gambro Dialysatoren GmbH & Co. KGFiltration membrane and process for producing the membrane

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3876738A (en)*1973-07-181975-04-08Amf IncProcess for producing microporous films and products
NZ190436A (en)*1978-05-151981-12-15Pall CorpPreparation of skinless hydrophilic alcohol insoluble polyamide membranes membranes casting resin solutions
US4673504A (en)*1980-10-271987-06-16Cuno Inc.Charge modified microporous membrane
US4473474A (en)*1980-10-271984-09-25Amf Inc.Charge modified microporous membrane, process for charge modifying said membrane and process for filtration of fluid
US4708803A (en)*1980-10-271987-11-24Cuno IncorporatedLiquid filtration using hydrophilic cationic isotropic microporous nylon membrane
US4702840A (en)*1982-02-051987-10-27Pall CorporationCharge modified polyamide membrane
US4707266A (en)*1982-02-051987-11-17Pall CorporationPolyamide membrane with controlled surface properties
US4915839A (en)*1984-03-151990-04-10Cuno, IncorporatedProcess for surface modifying a microporous membrane
US5120502A (en)*1988-04-111992-06-09Baxter International Inc.Pressure relief valve for membrane oxygenator
EP0571525A1 (en)*1991-02-111993-12-01OMMAYA, Ayub K.Spinal fluid driven artificial organ
US5334315A (en)*1992-01-171994-08-02Pall CorporationPriming system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3591493A (en)*1968-06-171971-07-06Rashid A ZeinehMethod for the treatment of biological fluids and apparatus therefor
EP0080680A2 (en)*1981-11-271983-06-08Sentron v.o.f.Reference electrode catheter
EP0098392A2 (en)*1982-07-021984-01-18Gambro Dialysatoren GmbH & Co. KGFiltration membrane and process for producing the membrane

Also Published As

Publication numberPublication date
JP3233928B2 (en)2001-12-04
FI104237B1 (en)1999-12-15
PT99148B (en)1999-05-31
KR100187556B1 (en)1999-06-01
EP0479187A1 (en)1992-04-08
FI931506A0 (en)1993-04-02
DE69128679T2 (en)1998-04-23
CA2092553C (en)2002-03-05
NO303768B1 (en)1998-08-31
IE80682B1 (en)1998-12-02
PT99148A (en)1993-10-29
EP0479187B1 (en)1998-01-14
FI931506L (en)1993-04-02
EP0478842A1 (en)1992-04-08
NO930993L (en)1993-03-18
CA2092553A1 (en)1992-04-06
FI104237B (en)1999-12-15
AU8659191A (en)1992-04-28
WO1992005864A1 (en)1992-04-16
JPH06504941A (en)1994-06-09
RU2072889C1 (en)1997-02-10
US5462667A (en)1995-10-31
IE913502A1 (en)1992-04-08
DE69128679D1 (en)1998-02-19
NO930993D0 (en)1993-03-18

Similar Documents

PublicationPublication DateTitle
AU646501B2 (en)Filter for liquor filtration
EP0637986B1 (en)Method and device for treating a parenteral emulsion-containing medicament fluid
EP1279408B1 (en)Venting system
US6168718B1 (en)Method for purifying blood plasma and apparatus suitable therefor
US5622626A (en)Multiple compartment filter and method for processing parenteral fluid
EP1993631B1 (en)Regeneratable filter for extracorporal treatment of liquids containing particles and use thereof
US5302299A (en)Biological semi-fluid processing assembly
McKinnon et al.Membrane filtration of pharmaceutical solutions
AU722640B2 (en)Method for purifying blood plasma and apparatus suitable therefor
AU6166199A (en)Biological fluid filter and system
JPH11267199A (en)Blood treatment method and device
DE102004037475A1 (en) Filter system for the membrane-separated, adsorptive treatment of particle-containing liquids
JPS6219177A (en) blood processing equipment
MainiA detoxification scheme for liver assist utilizing plasmapheresis, bioincompatible sorbents and dialysis
DE202006004182U1 (en)Filter system used in medicine for directly treating blood comprises a housing containing hollow fibers, a sieve for separating micro-particles from a plasma chamber and three-way valves for pumping liquids into a particle chamber
JPH0197472A (en) Multistage plasma separation method
JPH01113066A (en) Plasma separation method

Legal Events

DateCodeTitleDescription
MK14Patent ceased section 143(a) (annual fees not paid) or expired

[8]ページ先頭

©2009-2025 Movatter.jp